Receptos, a San Diego-based biopharmaceutical company backed by ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock, has filed to raise $86.3 million in an initial public offering. The company, which focuses on discovering, developing and commercializing therapies for immune and metabolic diseases, expects to list on the NASDAQ under the symbol RCPT. ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock were among the investors in a $27.56 million Series A round in November 2009.
